Products for Research Use Only

NF-κB-IN-19

CAT: 0804-HY-172201Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-172201Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NF-κB-IN-19 (Compound 8) is an NF-κB inhibitor. NF-κB-IN-19 effectively induces DNA damage, promotes the generation of ROS, and induces autophagy and apoptosis through the NF-κB signaling pathway in tumor cells. In addition, NF-κB-IN-19 can inhibit the levels of VEGF and HIF-1α, and exert antiproliferative activity in tumor cells through the PI3K/AKT and STAT-3 pathways. NF-κB-IN-19 can effectively overcome cisplatin resistance and has anti-tumor activity[1].
UNSPSC
12352005
Target
Akt; Apoptosis; Autophagy; HIF/HIF Prolyl-Hydroxylase; NF-κB; PI3K; Reactive Oxygen Species (ROS) ; STAT
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C(CCCC(O[Pt]([NH3])(Cl)(Cl)([NH3])Cl)=O)N1C/C(C(/C(C1)=C/C2=C(C=CC=C2)F)=O)=C\C3=CC=CC=C3F
Molecular Formula
C24H26Cl3F2N3O4Pt
Molecular Weight
759.92
References & Citations
[1]Wang M, et al. Discovery of a Novel EF24 Analogue-Conjugated Pt (IV) Complex as Multi-Target Pt (IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance. J Med Chem. 2025 Mar 13;68 (5) :5597-5615.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported